Shree Ganesh Remedies H1 Net Profit Falls to Rs 2.75 Crore

Revenue from operations for H1 FY27 stood at Rs 37.65 crore, while Net Profit After Tax reached Rs 2.75 crore.

Reader Takeaway: Revenue and profit both declined significantly year-on-year; management commentary on operational recovery is now critical for investors.

What just happened

Shree Ganesh Remedies Limited (SGRL) released its unaudited consolidated financial results for the half-year ended September 30, 2026. The board meeting concluded at 5:00 p.m. on October 31, 2026, confirming a challenging fiscal period for the manufacturer of bulk drug intermediates.

Why this matters

The company’s top-line and bottom-line figures show a contraction compared to the same period in the previous year. Revenue dropped from Rs 54.88 crore in H1 FY26 to Rs 37.65 crore in H1 FY27. Simultaneously, the Net Profit After Tax saw a steeper decline, falling to Rs 2.75 crore from Rs 8.40 crore in the corresponding period of 2025. This has resulted in the Basic EPS falling from 6.54 to 2.14.

Business Context

Shree Ganesh Remedies operates in the bulk drug intermediates segment. The company has clarified that its financial reporting consolidates its operations while excluding surplus from the Kamalam Foundation, as the latter is a Section 8 entity prohibited from distributing profits to its members.

Risks to watch

Investors should closely track the reasons behind the revenue slowdown. The significant drop in EPS and net margins suggests potential market demand issues or input cost pressures that shareholders must evaluate to determine if this is a temporary trend or a structural shift in performance.

What to track next

Watch for the company's next investor presentation or management call to gain insight into the specific segments or external factors that contributed to the revenue contraction and the steps being taken to restore profitability.